{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T12:14:04Z","timestamp":1774008844105,"version":"3.50.1"},"reference-count":5,"publisher":"PAGEPress Publications","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Reports"],"abstract":"<jats:p>Adalimumab (ADA), a monoclonal antibody targeting tumor necrosis factor (TNF)-\u03b1, is effective in treating moderate to severe psoriasis. The emergence of biosimilars, such as GP2017 (Hyrimoz\u00ae, Sandoz GmbH), has raised concerns about their safety and efficacy compared to the originator. This two-year observational study evaluated the effectiveness and safety of GP2017 in 171 patients from Emilia-Romagna, Italy. Patients were divided into two groups: 78 transitioned from the ADA originator, and 93 were biologic-naive. Changes in the Psoriasis Area and Severity Index (PASI) were analyzed. In the switch group, PASI scores remained stable, while the naive group achieved significant improvements (PASI 75: 52% at 3 months, 89% at 6 months). Adverse events leading to discontinuation were rare. The findings confirm that GP2017 is as effective and safe as the ADA originator, supporting its use as a cost-effective alternative in the treatment of psoriasis. Biosimilars play a crucial role in promoting equitable access to biologic therapies.<\/jats:p>","DOI":"10.4081\/dr.2025.10315","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T07:09:16Z","timestamp":1751353756000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy"],"prefix":"10.4081","volume":"18","author":[{"given":"Marco","family":"May Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vito","family":"Di Lernia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Peccerillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Bardazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Tabanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Melandri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Corazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Satolli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Conti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2549","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"37396","doi-asserted-by":"crossref","unstructured":"1. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008;106-15.","DOI":"10.1016\/j.jaad.2007.09.010"},{"key":"37397","unstructured":"2. European Medicines Agency. Hyrimoz. adalimumab. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hyrimoz"},{"key":"37398","doi-asserted-by":"crossref","unstructured":"3. Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-tosevere plaque psoriasis. Br J Dermatol 2018;178:509-19.","DOI":"10.1111\/bjd.16102"},{"key":"37399","doi-asserted-by":"crossref","unstructured":"4. Zhou X, Chen Z, Bi X. An Update Review of Biosimilars of Adalimumab in Psoriasis - Bioequivalence and Interchangeability. Drug Des Devel Ther 2021;15:2987-98.","DOI":"10.2147\/DDDT.S317382"},{"key":"37400","doi-asserted-by":"crossref","unstructured":"5. Reynolds KA, Pithadia DJ, Lee EB, et al. Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis. Am J Clin Dermatol 2020;21:483-91.","DOI":"10.1007\/s40257-020-00507-1"}],"container-title":["Dermatology Reports"],"original-title":[],"link":[{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10315\/9688","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10315\/9901","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10315\/9688","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T10:09:33Z","timestamp":1774001373000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/view\/10315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":5,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,12]]}},"URL":"https:\/\/doi.org\/10.4081\/dr.2025.10315","relation":{},"ISSN":["2036-7406","2036-7392"],"issn-type":[{"value":"2036-7406","type":"electronic"},{"value":"2036-7392","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}